Apart from the AP1189 granulate clinical trials

A randomized, double blind, placebo-controlled, phase II, multicentre trial to explore the efficacy and safety of oral AP1189 tablets administered at the dose 100 mg/day for 12 weeks in patients diagnosed with polymyalgia rheumatica and in remission on glucocorticoid

This study is looking into a new tablet called AP1189 for people with polymyalgia rheumatica (PMR) who are doing well on their current steroid medication. Researchers want to see if this new tablet, taken daily for 12 weeks, is safe and can help patients stay well without steroids.